Speaker Spotlight – 2016 National Conference Edition Part 7

drmetz

David C. Metz, MD

Professor of Medicine
Division of Gastroenterology
Hospital of University of Pennsylvania
Philadelphia, PA

pennmedicine

Bio:

Dr Metz is Professor of Medicine and Associate Chief for Clinical Affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is director of the Acid-Peptic Disease Program and codirector of the GI Physiology Laboratory, the Swallowing Disorders Program and the Neuroendocrine Tumor Program.

He is actively involved in clinical research, patient care, and teaching of students, residents, and fellows. Dr Metz’s clinical research program is particularly active in acid-peptic conditions including hypersecretory states such as Zollinger-Ellison syndrome, Helicobacter pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He also has particular expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. He has been a principal investigator on a number of trials evaluating upper gastrointestinal disease states. He is also active in national gastroenterology societies and was a prior member of the Liason Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative) and the US Food and Drug Administration Gastrointestinal Drugs Advisory Committee. He is vice chair of the North American Neuroendocrine Tumor Society (NANETS)

Dr Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa. He moved to the United States in 1986 and pursued a residency in internal medicine at Albert Einstein Medical Center in Philadelphia. He completed a fellowship in gastroenterology in Washington, DC, in the combined Georgetown/Veterans Affairs Medical Center/National Institutes of Health (NIH) program. He remained on staff at the NIH for 2 more years as a senior staff fellow, performing basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome specifically.

In 1993, Dr Metz moved to Philadelphia in the role of Assistant Professor in the clinician educator track at the University of Pennsylvania. He was promoted to Associate Professor in 1998 and Full Professor in 2003.

To make an appointment, please contact:

Bonnie Bennett at (215) 349-5562

Perelman Center for Advanced Medicine                                                                        South Pavilion, 4th Floor                                                                                                        3400 Civic Center Boulevard                                                                                 Philadelphia, PA 19104                                                                                                            (800) 789-PENN (7366)

For more information on Dr. David Metz and Penn Medicine at the University of Pennsylvania, please visit their website here.

Dr. Metz at the 2016 National NET Patient Conference:

Topic: The Role of the Gastroenterologist in Diagnosing and Treating NETs

When: Friday, September 23th, 2016 at 10:15AM*

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. Metz and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.

To check out some of our other speakers, click here!

Novartis Carcinoid Syndrome Quality of Life Survey

Happy Wednesday!

Today, Novartis Pharmacuticals has released a quality of life survey for NET patients diagnosed with Carcinoid Syndrome.

This survey is two parts and is said to be about 30 minutes long. For taking the first part, which you take immediately, you will be gifted a $20 Amazon gift card in 5-10 business days via email for your time. The second part is to be completed at a later date.

***My experience with the survey only took me about 10-15 minutes at most to complete!***

Here is the information:

QUALITY OF LIFE OF INDIVIDUALS WITH CARCINOID SYNDROME SYMPTOMS

Analysis Group is conducting an online survey study to understand the quality of life of patients with Carcinoid Syndrome and its symptoms. Your participation will advance the knowledge in this field. You will also receive a $20 gift card for Amazon.com for completing each survey, as a compensation for your time.

The Study

Analysis Group is seeking patients with Carcinoid Syndrome to share their experience through a two-part anonymous online survey. The first survey can be completed immediately and you will be invited to take a follow-up survey in 6 months. This study is non-interventional and will not require you to do anything beyond completing online survey questions about your experience with Carcinoid Syndrome symptoms. Analysis Group will email you a $20 gift card for Amazon.com within 5-10 business days of completing each survey.

To Participate

If you answer “Yes” to all the questions below, we welcome your participation in the online survey.

Have you been diagnosed with Carcinoid Syndrome (i.e., pattern of symptoms sometimes seen in people with carcinoid tumors)?

Have you ever experienced any of the following Carcinoid Syndrome symptoms (i.e., symptoms caused by a carcinoid tumor’s secretions of large amounts of the hormone serotonin)?

□ Carcinoid diarrhea

□ Carcinoid heart

□ Cramping

□ Cyanosis

□ Flushing

□ Peripheral edema

□ Wheezing

Are you at least 18 years of age?

Would you be able to spend 30 minutes to complete the survey?

Your participation is voluntary. Your responses expressed during the online survey session will be kept strictly confidential. Please direct any inquiries about the study to qol@analysisgroup.com.

To participate in the study and complete the online survey, please visit the survey link:

https://carcinoidsyndrome.healthresearchstudy.net/…

This research is funded by Novartis. Thank you in advance for your consideration

This is for patients in the USA only.

Lexicon Submits New Drug Application to FDA for the Treatment of Carcinoid Syndrome

BREAKING NEWS!!

Yesterday, March 30th, 2016, Lexicon Pharmaceuticals submitted a new drug application to the FDA for treatment of Carcinoid Syndrome!

Here is some of their press release:

“The Woodlands, Texas, March 30, 2016 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Lexicon has requested a Priority Review by the FDA as part of the NDA filing.

“The filing of the NDA for telotristat etiprate brings us one step closer to the possibility of bringing this innovative new investigational treatment to the market to improve the lives of the community of patients and caregivers who live with carcinoid syndrome on a daily basis,” said Lexicon President and Chief Executive Officer, Lonnel Coats. “We look forward to working closely with the FDA during the review process.”

The NDA filing is supported by the results from TELESTAR, a pivotal Phase 3 clinical trial of telotristat etiprate in patients with carcinoid syndrome, and TELECAST, a Phase 3 companion study to TELESTAR. Results from TELESTAR demonstrated a statistically significant reduction from baseline compared to placebo in the average number of daily bowel movements over the 12-week study period (p<0.001), meeting the study’s primary endpoint. Top-line results from TELECAST demonstrated a statistically significant reduction in urinary 5-hydroxyindoleacetic acid (5-HIAA, the main metabolite of serotonin) at week 12 (p<0.001) as compared to placebo, meeting that study’s primary endpoint. The proportions of patients with treatment-emergent adverse events, serious adverse events and discontinuation due to adverse events were generally similar between the telotristat etiprate and placebo arms in both studies.

Carcinoid syndrome is a rare disease affecting thousands of cancer patients with metastatic neuroendocrine tumors (mNETs) that have spread to the liver and other organs from the gastrointestinal tract. The condition is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as by facial flushing, abdominal pain, fatigue and, over time, heart valve damage.”

 

To download the rest of Lexicon’s exciting press release, you can get that here:

Telotristat Etiprate NDA Filing 

More information about Lexicon Pharmaceuticals, Inc. here!

I cannot wait to see where this advancement goes!

Be sure to follow me here and on Facebook for the most up-to-date information!

Until next time…

Best,

Tricia Wahmann-Knatz